News | September 02, 2022
NATCO Pharma to sell stake in Nativita and assets of Pharma division
NATCO to sell 15% of shareholding in Nativita for euro 3,45,000 to Pharmasyntez-Nord
NATCO to sell 15% of shareholding in Nativita for euro 3,45,000 to Pharmasyntez-Nord
According to industry sales data, Yondelis generated annual sales of $49.7 million for the twelve months ending June 2022 in the US market.
He has over 25+ years of experience in the pharmaceutical Industry and has been working with the company for the past 6 years
The company has reported total income of Rs. 918.9 crores during the period ended June 30, 2022.
The product will be launched by NATCO's commercial partner Viatris.
This lawsuit has been filed in the Pennsylvania Federal Court. NATCO and its marketing partner Mylan
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
Natco Pharma has received approval for Covid 19 drug molnupiravir capsules 200 mg. for Indian market, which will be sold under brand name Molnunat
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)